Menu

Pharmaceuticals

 

 

Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)

, , ,

February 15, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck’s Supplemental New Drug Applications for ZETIA® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal […]

Lilly Diabetes Helps Inspiring Students with Type 1 Diabetes Attend College Through Scholarship Donation

, , , ,

Company supports Diabetes Scholars Foundation Scholarship fund for fourth year in a row ROLLING MEADOWS, Ill. and INDIANAPOLIS, Feb. 11, 2016 /PRNewswire/ — Attending college is a major milestone for many young people, but for those with type 1 diabetes, the journey can be extra demanding. Not only do these students juggle class schedules, assignments […]

American Diabetes Association® Survey Shows Summer Camp Can Positively Impact Children’s Disease Management Skills, Confidence and Stress

, , , ,

Lilly Diabetes commits $93,000 to support Association “Camperships” INDIANAPOLIS and ALEXANDRIA, Va., Feb. 3, 2016 /PRNewswire/ — A three-year survey by the American Diabetes Association (Association) shows attending summer camp can do much more than lift the spirits of children with type 1 diabetes. Surveys conducted with caregivers before and after their child attended an […]

Lilly and Roche Diagnostics to Collaborate on Alzheimer’s Disease Adjunct Diagnostic Tool

, , , ,

INDIANAPOLIS, Jan. 27, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42. Together with tau tangles, the presence of amyloid in the brain is a key marker of Alzheimer’s disease, a condition […]

Edwards Receives FDA Approval For Expanded Indication Study Of SAPIEN 3 Valve

, , , ,

IRVINE, Calif., Jan. 15, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug Administration approval for an expanded indication study of its most advanced transcatheter aortic heart valve, the Edwards SAPIEN 3 valve. The investigational device exemption […]

Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening

, , , ,

Significant Development in the War on Cancer SAN DIEGO–(BUSINESS WIRE)–Jan. 10, 2016– Illumina, Inc. (NASDAQ:ILMN) today announced GRAIL, a new company formed to enable cancer screening from a simple blood test. Powered by Illumina sequencing technology, GRAIL will develop a pan-cancer screening test by directly measuring circulating nucleic acids in blood. Detecting cancer at the […]

World Health Organization to Review Merck’s Investigational Ebola Vaccine for Emergency Use Assessment and Listing

, , ,

KENILWORTH, N.J. December 23, 2015 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the application for Emergency Use Assessment and Listing (EUAL) for the company’s investigational Ebola Zaire vaccine, V920 (rVSV∆G-ZEBOV-GP, live attenuated), has been accepted for review by the World Health Organization (WHO). According to the WHO, […]

Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases

, , ,

The novel joint venture focuses on fundamental breakthrough treatments through first systemic application of promising CRISPR-Cas9 gene editing technology / Bayer is investing USD 335 million in a long-term alliance with CRISPR Therapeutics through new Bayer LifeScience Center unit / The joint venture will combine two leading knowledge areas: CRISPR-Cas9 from CRISPR Therapeutics as well […]

GSK completes divestment of rights to ofatumumab for auto-immune indications to Novartis

, , , ,

21 December 2015, London – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the completion of its transaction to divest its rights to ofatumumab for auto-immune indications to Novartis Pharma AG (“Novartis Pharma”), a subsidiary of Novartis AG, following regulatory approval. The consideration payable by Novartis Pharma to GSK may reach up to $1,034 million and comprises a series […]

GSK’s global HIV business ViiV Healthcare to acquire Bristol-Myers Squibb’s R&D HIV assets

, , , , ,

Two transactions further strengthen HIV pipeline and outlook 18 December 2015, London – GlaxoSmithKline plc (LSE: GSK) today announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb, to acquire its late-stage HIV R&D assets; and to acquire Bristol-Myers Squibb’s portfolio of preclinical and discovery stage HIV research assets. Under the […]

«‹ 12 13 14 15›»